PharmaCyte Biotech, Inc. PMCB
When we released a special report on PMCB back on Tuesday of last week, we commented on the promising nature of trials the company currently has underway relating to various treatments based on its Cell-in-a-Box® technology.
At the end of last week, PharmaCyte announced some promising research specifically pertaining to its diabetes treatment, with the claim that it can actually reverse Type-1 Diabetes in mice.The full paper can be found at http://www.nature.com/articles/mtm201511. Human trials are the next step to take, and needless to say, should the treatment prove effective using PMCB’s encapsulation technology (that we described in our initial report,) acquisition by a large pharmaceutical company could become a very real possibility.
That also seems to be the thinking on the Street, as PMCB has made some impressive strides on the chart over the past several sessions. From the low of .12 that we observed in this play on 04/08, it has made its way up as high as .22; a respectable 83% overall increase. That impressive high came during yesterday’s session in conjunction with a breach of the current 200DMA of .19.
PMCB will be one that we want to keep on continuous watch due to its potentially industry-disruptive diabetes treatment.
Pazoo, Inc. PZOO
PZOO has been a flipper’s dream since we re-initiated coverage on it just a couple of weeks ago. Yesterday’s low registered as .008 before the stock bounced back to .0097, a 21% intraday swing.
It was the same story on Wednesday; we saw PZOO dip to a low of .0074 before returning as high as .0103 (+39%) We’ve continually stated that we’d like to see the stock trading at or above the .008 range which, for the most part, it has continued to do.
CEO David Cunic appeared in an audio interview yesterday, and this morning we’re seeing another PR directing our attention to an 8-K filing which outlines a recent agreement, among other things, so our readers might want to check out those links.
In the meantime, we’ll be on the lookout for upcoming intraday gain opportunities from PZOO, such as those that it has delivered numerous time over the past several sessions.
Identiv, Inc. INVE
We also want to make a quick mention of INVE, which made a solid 14% move yesterday as it traded in a range from 11.12-12.67. It came on over ten times the 3-month average volume, so we’ll be observing this one as the week draws to a close, and possibly into next week.
RXII, ONCY, ZBB, UNXL